Learning Objectives:

At the conclusion of this activity participants will be able to:

1.    Discuss the signs/symptoms of cardiac amyloidosis and review the approach to diagnosis
2.    Discuss the heritable forms of cardiac amyloidosis and implications for screening
3.    Outline the approaches to treat cardiac amyloidosis, their efficacy, and impact on prognosis

Presenter:

Frederick Ruberg, MD, Presenter, has received Grant/Research Support with Pfizer, Alnylam Pharmaceuticals, Akcea Therapeutics, Alexion Pharmaceuticals, and a consultant with Attralus on the topics of Clinical trial design, Cardiac amyloidosis research, and one-off educational event to raise awareness of cardiac amyloidosis.

Faculty member does plan on discussing unlabeled/investigational uses of a commercial product: Tc99m Pyrophosphate imaging for diagnosis in ATTR amyloidosis, diflunisal for treatment in ATTR amyloidosis

 

Session date: 
04/08/2022 - 9:00am to 10:00am EDT
Location: 
Boston University School of Medicine
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • 1.00 MA Risk Management
  • 1.00 Participation

Please login or register to take this course.